WBRT
WBRT is a radiation therapy with 13 clinical trials. Currently 1 active trials ongoing. Historical success rate of 62.5%.
Success Metrics
Based on 5 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
7
Mid Stage
4
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
62.5%
5 of 8 finished
37.5%
3 ended early
1
trials recruiting
13
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Whole Brain Radiation Therapy Alone vs. Radiosurgery for SCLC Patients With 1-10 Brain Metastases
Camrelizumab Combined With Local Treatment in NSCLC Patients With BM
Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma
Study of Tumour Focused Radiotherapy for Bladder Cancer
IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases
Clinical Trials (13)
Whole Brain Radiation Therapy Alone vs. Radiosurgery for SCLC Patients With 1-10 Brain Metastases
Camrelizumab Combined With Local Treatment in NSCLC Patients With BM
Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma
Study of Tumour Focused Radiotherapy for Bladder Cancer
IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases
Combination Chemotherapy With or Without Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer
A Study of Whole Brain Radiation Therapy and Capecitabine in Breast Cancer Participants With Newly Diagnosed Brain Metastasis
Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid)
Phase Ⅲ Trial of WBRT Versus Erlotinib Concurrent Whole-brain Radiation Therapy as first-line Treatment for Patients With Multiple Brain Metastases From Non-small-cell Lung Cancer(ENTER): a Multicentre, Open-label, Randomised Study
Radiosurgery With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
Comparator-Controlled Study for EGFR(+) Patients With Multiple BMs From NSCLC (BROKE) (EGFR-epidermal Growth Factor Receptor;BM-brain Metastases)
Brain Mets - Capecitabine Plus Sunitinib and WBRT
Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Brain Metastases
All 13 trials loaded
Drug Details
- Intervention Type
- RADIATION
- Total Trials
- 13